Cancer Therapeutics Stocks
Biotechnology firms in this vertical specialize in the R&D of precision oncology assets ranging from antibody-drug conjugates and cell therapies to targeted small molecules and radiopharmaceuticals. Revenue models depend on successful progression through rigorous FDA clinical trial phases, where binary outcomes regarding safety and efficacy drive significant valuation volatility.
As of Oct 23, 2026, Cancer Therapeutics has 183 US-listed companies worth $571B combined. The median member moved +1.5% over the past week; GMAB led among the 25 largest at +18.4% and RCUS trailed at -16.2%.
Companies in Cancer Therapeutics
- MRK – Merck & Company Inc, $363B
- RVMD – Revolution Medicines Inc, $40.2B
- GMAB – Genmab AS, $26.9B
- EXEL – Exelixis Inc, $16.2B
- SMMT – Summit Therapeutics PLC, $12.3B
- IBRX – Immunitybio Inc, $8.8B
- IOVA – Iovance Biotherapeutics Inc, $6.4B
- CGON – CG Oncology, Inc. Common stock, $5.3B
- ERAS – Erasca Inc, $5.1B
- TNGX – Tango Therapeutics Inc, $4.5B
- RLAY – Relay Therapeutics Inc, $4B
- TLX – Telix Pharmaceuticals Limited, $3.8B
- VCYT – Veracyte Inc, $3.7B
- IDYA – Ideaya Biosciences Inc, $3.5B
- CELC – Celcuity LLC, $3.2B
- PBLS – Parabilis Medicines, Inc. Common Stock, $3.1B
- ELVN – Enliven Therapeutics Inc., $2.9B
- RCUS – Arcus Biosciences Inc, $2.8B
- SLS – Sellas Life Sciences Group Inc, $2.3B
- NEO – NeoGenomics Inc, $2.1B
- IMNM – Immunome Inc, $2.1B
- ZYME – Zymeworks Inc. Common Stock, $1.9B
- VIR – Vir Biotechnology Inc, $1.8B
- NVCR – Novocure Ltd, $1.8B
- NUVB – Nuvation Bio Inc, $1.7B
- URGN – UroGen Pharma Ltd, $1.7B
- NBTX – Nanobiotix, $1.7B
- IMCR – Immunocore Holdings Ltd, $1.5B
- INBX – Inhibrx Biosciences, Inc., $1.4B
- AAPG – Ascentage Pharma Group International, $1.4B
- DRTS – Alpha Tau Medical Ltd, $1.3B
- REPL – Replimune Group Inc, $1.3B
- ORIC – Oric Pharmaceuticals Inc, $1.2B
- BCAX – Bicara Therapeutics Inc. Common Stock, $1.2B
- JANX – Janux Therapeutics Inc, $1.1B
- IMTX – Immatics NV, $1B
- ANL – Adlai Nortye Ltd. American Depositary Shares, $999M
- CGEM – Cullinan Oncology LLC, $961M
- KURA – Kura Oncology Inc, $944M
- AKTS – Aktis Oncology, Inc. Common stock, $890M
- RIGL – Rigel Pharmaceuticals Inc, $881M
- CRVS – Corvus Pharmaceuticals Inc, $876M
- SLBT – SL Science Holding Limited Ordinary Shares, $869M
- VSTM – Verastem Inc, $781M
- GERN – Geron Corporation, $771M
- OBX – Obsidian Therapeutics, Inc. Common Stock, $741M
- FTH – Faeth Therapeutics, Inc., $733M
- NVCT – Nuvectis Pharma Inc, $716M
- CADL – Candel Therapeutics Inc, $709M
- OLMA – Olema Pharmaceuticals Inc, $684M
- STLN – The Oncology Institute, Inc., $655M
- FLGT – Fulgent Genetics Inc, $591M
- CTMX – CytomX Therapeutics Inc, $556M
- ETRA – Electra Therapeutics, Inc. Common stock, $549M
- DCTH – Delcath Systems Inc, $534M
- CBIO – Crescent Biopharma, Inc., $532M
- PBYI – Puma Biotechnology Inc, $506M
- AUTL – Autolus Therapeutics Ltd, $482M
- ARVN – Arvinas Inc, $472M
- BLSM – BlossomHill Therapeutics, Inc. Common Stock, $458M
- EIKN – Eikon Therapeutics, Inc. Common Stock, $408M
- INDP – Indaptus Therapeutics Inc, $380M
- AONC – American Oncology Network Inc., $336M
- ARTV – Artiva Biotherapeutics, Inc. Common Stock, $332M
- CCCC – C4 Therapeutics Inc, $325M
- AGEN – Agenus Inc, $273M
- BBOT – BridgeBio Oncology Therapeutics, Inc., $265M
- CATX – Perspective Therapeutics Inc., $259M
- PRLD – Prelude Therapeutics Inc, $258M
- IMRX – Immuneering Corp, $255M
- FATE – Fate Therapeutics Inc, $231M
- GLSI – Greenwich Lifesciences Inc, $226M
- PYXS – Pyxis Oncology Inc, $220M
- MGNX – MacroGenics Inc, $218M
- ADCT – ADC Therapeutics SA, $217M
- LYEL – Lyell Immunopharma Inc, $213M
- ZNTL – Zentalis Pharmaceuticals Llc, $209M
- WHWK – Whitehawk Therapeutics, Inc., $194M
- STRO – Sutro Biopharma, $181M
- ALXO – Alx Oncology Holdings , $173M
- ADAG – Adagene Inc, $165M
- MOLN – Molecular Partners AG ADR, $165M
- IPHA – Innate Pharma, $160M
- CHRS – Coherus BioSciences Inc, $156M
- VRXA – Veraxa Biotech AG Ordinary Shares, $156M
- CMPX – Compass Therapeutics Inc., $150M
- CLLS – Cellectis SA, $135M
- HURA – TuHURA Biosciences Inc, $117M
- GNLX – Genelux Corporation Common Stock, $114M
- FHTX – Foghorn Therapeutics Inc, $110M
- BDTX – Black Diamond Therapeutics Inc, $105M
- PMVP – Pmv Pharmaceuticals Inc, $105M
- INO – Inovio Pharmaceuticals Inc, $102M
- OKUR – OnKure Therapeutics, Inc., $97.6M
- ATRA – Atara Biotherapeutics Inc, $96M
- KZIA – Kazia Therapeutics Ltd ADR, $89.7M
- ACRV – Acrivon Therapeutics, Inc. Common Stock, $81.8M
- CTOR – Citius Oncology, Inc., $81.2M
- NTHI – NeOnc Technologies Holdings, Inc. Common Stock, $79.2M
- OSTX – OS Therapies Incorporated, $75.8M
- RFL – Rafael Holdings, Inc., $74.4M
- ONCY – Oncolytics Biotech Inc, $71.8M
- MAIA – MAIA Biotechnology Inc., $71.6M
- CRDF – Cardiff Oncology Inc, $70.1M
- APLM – Apollomics Inc. Class A Ordinary Shares, $67.8M
- CSBR – Champions Oncology Inc, $66.9M
- PDSB – PDS Biotechnology Corp, $66.4M
- XBIT – XBiotech Inc, $65.9M
- BOLD – Boundless Bio, Inc. Common Stock, $58.5M
- RNXT – RenovoRx Inc, $52.4M
- INKT – Mink Therapeutics Inc, $52.2M
- ELTX – Elicio Therapeutics Inc., $50.5M
- LONA – LeonaBio, Inc., $49M
- HOWL – Werewolf Therapeutics Inc, $45.2M
- ACET – Adicet Bio Inc, $42.4M
- TIL – Instil Bio Inc., $41.6M
- LITS – Lite Strategy, Inc., $36.2M
- GNTA – Genenta Science SpA ADR, $34.8M
- IMMP – Immutep Ltd ADR, $32.1M
- CVM – CEL-SCI Corp, $31.5M
- ATNM – Actinium Pharmaceuticals Inc, $30.6M
- RNAZ – Transcode Therapeutics Inc, $30.1M
- BCTX – Briacell Therapeutics Corp, $30.1M
- CNTX – Context Therapeutics Inc, $28.9M
- NXTC – NextCure Inc, $24.9M
- SHPH – Shuttle Pharmaceuticals Inc, $24.2M
- ESLA – Estrella Immunopharma Inc., $23.3M
- BYSI – BeyondSpring Inc, $23M
- AKTX – Akari Therapeutics PLC, $21.2M
- MRKR – Marker Therapeutics Inc, $17.3M
- CCM – Concord Medical Services Holdings, $16.2M
- RADX – Radiopharm Theranostics Limited American Depositary Shares, $15.8M
- CTXR – Citius Pharmaceuticals Inc, $14.6M
- ACTU – Actuate Therapeutics, Inc. Common stock, $14.5M
- GTBP – GT Biopharma Inc, $14.5M
- ALLR – Allarity Therapeutics Inc, $13.9M
- INAB – In8bio Inc, $13.8M
- TCRX – Tscan Therapeutics Inc, $13.8M
- TVRD – Tvardi Therapeutics, Inc., $13.7M
- CLRB – Cellectar Biosciences Inc, $13.1M
- TPST – Tempest Therapeutics Inc, $12.8M
- INTS – Intensity Therapeutics, Inc. Common stock, $11.9M
- LSTA – Lisata Therapeutics Inc., $11.2M
- PHIO – Phio Pharmaceuticals Corp, $10.9M
- TOVX – Theriva Biologics Inc., $9.9M
- LTRN – Lantern Pharma Inc, $9.6M
- KPTI – Karyopharm Therapeutics Inc, $8.8M
- AMS – American Shared Hospital Service, $8.4M
- CNSP – CNS Pharmaceuticals Inc, $7.8M
- BOLT – Bolt Biotherapeutics, $7.7M
- APRE – Aprea Therapeutics Inc, $7.5M
- OSRH – OSR Holdings Inc, $7.4M
- SNTI – Senti Biosciences Inc, $7.1M
- AIM – AIM ImmunoTech Inc, $6.7M
- MBRX – Moleculin Biotech Inc, $6.3M
- IMNN – Imunon Inc, $6.1M
- BGMS – Bio Green Med Solution, Inc., $5.5M
- XBIO – Xenetic Biosciences Inc, $5.2M
- PCSA – Processa Pharmaceuticals Inc, $5.1M
- LIMN – Liminatus Pharma, Inc. Class A Common Stock, $5M
- PPCB – Propanc Biopharma, Inc. Common Stock, $4.8M
- NCNA – NuCana PLC, $4.1M
- MDCX – Medicus Pharma Ltd. Common Stock, $3.8M
- PMCB – PharmaCyte Biotech Inc, $3.7M
- ERNA – Eterna Therapeutics Inc, $3.7M
- APVO – Aptevo Therapeutics Inc, $3.1M
- MBIO – Mustang Bio Inc, $3.1M
- GOVX – GeoVax Labs Inc, $2.9M
- CLDI – Calidi Biotherapeutics Inc., $2.8M
- ONCO – Onconetix Inc, $2.5M
- BCAB – Bioatla Inc, $2.5M
- PPBT – Purple Biotech, $2.5M
- KAPA – Kairos Pharma, Ltd., $2M
- GNPX – Genprex Inc, $1.7M
- CRIS – Curis Inc, $981,914
- CERO – CERo Therapeutics Holdings, Inc. Common Stock, $644,678
- KRBP – Kiromic Biopharma Inc, $214,931
- TCON – TRACON Pharmaceuticals Inc, $109,725
- VINC – Vincerx Pharma, Inc. Common Stock, $68,045
- PBLA – Panbela Therapeutics Inc, $14,564
- BPTH – Bio Path Holdings Inc, $10,059
- EFTR – Effector Therapeutics Inc, $940
- CALA – Calithera Biosciences Inc, $487